Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca Galida NDA Delayed Until 2007 Due To PPAR Safety Concerns

Oct 11 2004

• By The Pink Sheet

Related Content

Merck After Vioxx: No Merger, But No Big Near-Term Launches

Oct 04 2004

Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar

May 03 2004

Exanta Superiority To Warfarin Could Reduce Safety Concerns – Cmte.

Sep 20 2004

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window